Editas Medicine (EDIT) closed at $2.75 on November 9, 2026, up 7.0% from the previous close, on volume of 3,623,535 shares (30-day average 2,194,633).
Data as of November 9, 2026.
9-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Tue, 10-Nov 5:50 AM ET)
Editas Medicine GAAP EPS of -$0.15 beats by $0.04, revenue of $10.37M beats by $5.84M
Seeking Alpha News (Mon, 9-Nov 7:03 AM ET)
Editas Medicine Announces Third Quarter 2026 Results and Business Updates
Globe Newswire (Mon, 9-Nov 7:00 AM ET)
Globe Newswire (Wed, 14-Oct 9:00 AM ET)
Globe Newswire (Thu, 8-Oct 7:00 AM ET)
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
Globe Newswire (Wed, 9-Sep 9:00 AM ET)
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
Globe Newswire (Tue, 8-Sep 7:00 AM ET)
Editas Medicine to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 1-Sep 9:00 AM ET)
Editas Medicine’s $319.4M Offering Signals Major Cash Infusion—and Sets Critical Clinical Milestones
Market Chameleon (Wed, 27-May 6:31 AM ET)
Market Chameleon (Mon, 9-Mar 7:14 AM ET)
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Editas Medicine trades on the NASDAQ stock market under the symbol EDIT.
As of November 9, 2026, EDIT stock price climbed to $2.75 with 3,623,535 million shares trading.
EDIT has a beta of 3.07, meaning it tends to be more sensitive to market movements. EDIT has a correlation of 0.21 to the broad based SPY ETF.
EDIT has a market cap of $422.02 million. This is considered a Small Cap stock.
Last quarter Editas Medicine reported $12 million in Revenue and -$.15 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.13.
In the last 3 years, EDIT traded as high as $11.69 and as low as $.91.
The top ETF exchange traded funds that EDIT belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
EDIT has underperformed the market in the last year with a return of +11.3%, while the SPY ETF gained +13.3%. In the last 3 month period, EDIT fell short of the market, returning -4.5%, while SPY returned -2.4%. However, in the most recent 2 weeks EDIT has outperformed the stock market by returning +14.6%, while SPY returned -1.7%.
EDIT support price is $2.42 and resistance is $2.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EDIT shares will trade within this expected range on the day.
